Why the study?
Does ZENECA ZD6888 cause histopathological changes in the juxtaglomerular apparatus in rats?
Does ZENECA ZD6888 cause histopathological changes in the juxtaglomerular apparatus in rats?
Administration of the angiotensin II antagonist ZD6888 in rats leads to dose-related histopathological changes in the juxtaglomerular apparatus, similar to those seen with ACE inhibitors.
Answers are grounded in this paper and cite their sources.
Animal data link ZD6888 to renal histopathology; hypothesis-generating for class effects and human safety monitoring.
Male and female Alderley Park rats were treated for 26 wk with ZENECA ZD6888, an angiotensin II (AII) antagonist, at doses of 25, 50, and 250 mg/kg/day and the kidneys examined by light and electron microscopy. Nephropathy (tubular degeneration and regeneration), thickening of the basal lamina, mononuclear cell infiltration, and hypertrophy and hyperplasia of the juxtaglomerular apparatus were seen by light microscopy. Ultrastructurally, juxtaglomerular cell granules were increased in number and displayed substantial structural heterogeneity. In some cells, granules contained paracrystalline inclusions while others consisted predominantly of myelinic debris. Evidence of conversion of arteriolar smooth muscle cells into juxtaglomerular cells and their degeneration was also obtained by electron microscopy. The juxtaglomerular changes were treatment- and dose-related and were attributed to an exaggerated pharmacological action of the compound, that is, ZD6888-mediated blockade of AII receptors leading to competitive inhibition of the AII-mediated release of renin. The resemblance between the findings seen in the present study following administration of an AII antagonist and those due to angiotensin-converting enzyme inhibitors reported by others was striking.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: